Global effort toward HIV cure published in Special Issue of AIDS Research and Human Retroviruses

Researchers have shown that despite effective combined antiretroviral therapy (cART), HIV can hide in the spleen of patients with no detectable HIV in their blood. The study confirming the spleen as an HIV sanctuary is part of a comprehensive collection of articles describing the broad scope and current status of the ongoing global effort toward an HIV cure, published in the fourth annual Special Issue on HIV Cure Research of AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The issue is available free on the AIDS Research and Human Retroviruses website.

David Nolan, BioInforExperts (Thibodaux, LA) and University of Florida (Gainesville) and colleagues from University of California Los Angeles David Geffen School of Medicine and University of California at San Francisco coauthored the article entitled "The Spleen Is an HIV-1 Sanctuary During Combined Antiretroviral Therapy." The researchers used advanced technology, including single genome sequencing and droplet digital polymerase chain reaction (ddPCR) capable of identifying very small amounts of viral DNA in tissue samples from HIV-infected individuals.

In the article "Natural Products and HIV/AIDS," Daniele Cary and B. Matija Peterlin, University of California at San Francisco discuss the many effective therapeutic compounds derived from natural products, including those able to suppress HIV and reactivate latent virus, as well as a recent report of a combination of 13 traditional Chinese herbs capable of achieving a functional cure.

"If We Build It, Will They Come? Perceptions of HIV Cure-Related Research by People Living with HIV in Four U.S. Cities: A Qualitative Focus Group Study" is the title of an article by Laurie Sylla et al. from defeatHIV Community Advisory Board (Seattle, WA), Project Inform and Delaney AIDS Research Enterprise (DARE) CAB (Los Angeles, CA), amfAR Institute for HIV Cure Research CAB and Collaboratory of AIDS Researchers for Eradication (CARE) CAB, (Palm Springs, CA), The University of North Carolina at Chapel Hill, and University of California at San Francisco School of Medicine. The authors provide valuable insights and perspectives on how people living with HIV view both a functional cure and a sterilizing or eradicating cure. The differences, and skepticism about whether medicine will be able to eliminate HIV from the body, can affect patients' willingness to participate in the HIV cure studies needed to advance biomedical research.

"The 2018 Special Issue on HIV Cure Research contains an excellent cross section of research activity in the field, capturing the current debates and discussions driving the field," says Thomas Hope, PhD, Editor-in-Chief of AIDS Research and Human Retroviruses and Professor of Cell and Molecular Biology at Northwestern University, Feinberg School of Medicine (Chicago, IL). "The questions relating to how a cure would impact the lives of people living with HIV/AIDS is especially interesting and informative. It is surprising that many are not necessarily excited that a functional cure for HIV would improve their lives."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research explores how omega-3 and omega-6 fatty acids may impact cancer rates